Compugen Ltd. (NASDAQ:CGEN) – Research analysts at Jefferies Group decreased their FY2018 earnings per share estimates for Compugen in a research report issued on Wednesday. Jefferies Group analyst P. Welford now anticipates that the biotechnology company will earn ($0.85) per share for the year, down from their prior estimate of ($0.82). Jefferies Group also issued estimates for Compugen’s FY2019 earnings at ($1.02) EPS, FY2020 earnings at ($1.22) EPS and FY2021 earnings at ($1.40) EPS.
CGEN has been the subject of a number of other research reports. Zacks Investment Research upgraded Compugen from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a research report on Friday, January 19th. ValuEngine cut Compugen from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st.
Compugen (NASDAQ:CGEN) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported ($0.18) EPS for the quarter.
Institutional investors and hedge funds have recently modified their holdings of the business. Paloma Partners Management Co purchased a new stake in Compugen in the fourth quarter worth about $105,000. Virtu Financial LLC purchased a new stake in Compugen in the fourth quarter worth about $162,000. Jane Street Group LLC purchased a new stake in Compugen in the fourth quarter worth about $192,000. Benjamin F. Edwards & Company Inc. increased its position in Compugen by 35.4% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 85,300 shares of the biotechnology company’s stock worth $213,000 after buying an additional 22,305 shares in the last quarter. Finally, Anson Funds Management LP purchased a new stake in Compugen in the fourth quarter worth about $281,000. Institutional investors and hedge funds own 23.06% of the company’s stock.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.